Tag: HMO

From Breast Milk to Bottle: Science and Strategy Behind BENEO and WACKER’s HMO Launch

Olivier Roques, CEO of BENEO In a strategic effort to enhance early-life nutrition, BENEO and WACKER have partnered to develop and globally launch 2’-Fucosyllactose (2’-FL), the most abundant and well-researched human milk oligosaccharide (HMO). This collaboration combines BENEO’s extensive expertise in prebiotics with WACKER’s advanced fermentation technology, highlighting their shared[Read More…]

Read More

Preclinical study shows combination of chicory-derived prebiotics and HMO for toddler gut health

The science-driven, ingredient-specific research, conducted in collaboration with leading academic partner ETH Zurich, focused on microbial composition and metabolic effects in early nutrition A new preclinical study, conducted by Pudenz et al., i demonstrates that combining chicory-derived inulin-type fructans with the human milk oligosaccharide (HMO) 2’-fucosyllactose (2’-FL) leads to additive, and even synergistic,[Read More…]

Read More

Mengniu driving development of innovative HMO nutritional ingredients

Mengniu emerge as a pioneer in developing nutritional ingredients, particularly through groundbreaking advancements in HMO technology In August 2024, Synaura Biotechnology a subsidiary of China Mengniu Dairy Company Limited, received GRAS certification from the U.S. Food and Drug Administration (FDA) for its 2′-FL (2′-Fucosyllactose), making it the first and only[Read More…]

Read More

Illuma unveils next-generation HMO innovations

Illuma has swiftly launched many remarkable HMO products in China Recently at Nestlé’s headquarters in Vevey, Switzerland, illuma, a global super premium brand of maternal and infant nutrition under Nestlé, began its “Human Milk Oligosaccharides (HMO) Research Traceability Journey”. With a focus on the most recent advancements in the field of human milk research, particularly[Read More…]

Read More

Wyeth launches China’s first infant formula with two types of HMOs

This clinically proven product offers substantial advantages for the general well-being of newborns between the ages of 0 and 12 months Filling a gap in the local HMO market, the recently released illuma HMO Liquid Formula is the first in China to contain two essential HMOs, 2′-Fucosyllactose (2′-FL) and Lacto-N-neotetraose (LNnT). This clinically proven product offers[Read More…]

Read More

dsm firmenich announces approval of HMO ingredients for infant nutrition in Australia and New Zealand

dsm-firmenich is the first HMO manufacturer to apply and obtain approval for the four HMOs in this region dsm-firmenich, a leading innovator in health, nutrition and beauty, announced that it has gained approval for an additional four human milk oligosaccharide (HMO) ingredients for use as nutritive substances in infant formula products in[Read More…]

Read More

dsm-firmenich achieves regulatory clearance in China for HMO ingredients

The two HMOs that received approval in China include GlyCare 2’-fucosyllactose (2’-FL), the most prevalent HMO in human breast milk, and GlyCare lacto-N-neotetraose (LNnT) dsm-firmenich, the leading innovator in health, nutrition and beauty, announced that two of its human milk oligosaccharide (HMO) ingredients have been approved as fortifiers for infant[Read More…]

Read More
 
 

Follow us

Let's connect on any of these social networks!